Skip to content
naulon

Not checkedNot checked for notices yet.

Medroxyprogesterone improves nocturnal breathing in postmenopausal women with chronic obstructive pulmonary disease

Aittokallio Tero, Utriainen Karri, Saaresranta Tarja and 1 more

Respiratory Research · 2005

doi:10.1186/1465-9921-6-28 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>Progestins as respiratory stimulants in chronic obstructive pulmonary disease (COPD) have been investigated in males and during wakefulness. However, sleep and gender may influence therapeutic responses. We investigated the effects of a 2-week medroxyprogesterone acetate (MPA) therapy on sleep and nocturnal breathing in postmenopausal women.</p> <p>Methods</p> <p>A single-blind placebo-controlled trial was performed in 15 postmenopausal women with moderate to severe COPD. A 12-week trial included 2-week treatment periods with placebo and MPA (60 mg/d/14 days). All patients underwent a polysomnography with monitoring of SaO<sub>2 </sub>and transcutaneous PCO<sub>2 </sub>(tcCO<sub>2</sub>) at baseline, with placebo, with medroxyprogesterone acetate (MPA 60 mg/d/14 days), and three and six weeks after cessation of MPA.</p> <p>Results</p> <p>Thirteen patients completed the trial. At baseline, the average ± SD of SaO<sub>2 </sub>mean was 90.6 ± 3.2 % and the median of SaO<sub>2 </sub>nadir 84.8 % (interquartile range, IQR 6.1). MPA improved them by 1.7 ± 1.6 %-units (95 % confidence interval (CI) 0.56, 2.8) and by 3.9 %-units (IQR 4.9; 95% CI 0.24, 10.2), respectively. The average of tcCO<sub>2 </sub>median was 6.0 ± 0.9 kPa and decreased with MPA by 0.9 ± 0.5 kPa (95% CI -1.3, -0.54). MPA improved SaO<sub>2 </sub>nadir and tcCO<sub>2 </sub>median also during REM sleep. Three weeks after cessation of MPA, the SaO<sub>2 </sub>mean remained 1.4 ± 1.8 %-units higher than at baseline, the difference being not significant (95% CI -0.03, 2.8). SaO<sub>2 </sub>nadir was 2.7 %-units (IQR 4.9; 95% CI 0.06, 18.7) higher than at baseline. Increases in SaO<sub>2 </sub>mean and SaO<sub>2 </sub>nadir during sleep with MPA were inversely associated with baseline SaO<sub>2 </sub>mean (r = -0.70, p = 0.032) and baseline SaO<sub>2 </sub>nadir (r = -0.77, p = 0.008), respectively. Treatment response in SaO<sub>2 </sub>mean, SaO<sub>2 </sub>nadir and tcCO<sub>2 </sub>levels did not associate with pack-years smoked, age, BMI, spirometric results or sleep variables.</p> <p>Conclusion</p> <p>MPA-induced respiratory improvement in postmenopausal women seems to be consistent and prolonged. The improvement was greater in patients with lower baseline SaO<sub>2 </sub>values. Long-term studies in females are warranted.</p>

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.